The Clinical Pharmacokinetics of Cladribine

@article{Liliemark1997TheCP,
  title={The Clinical Pharmacokinetics of Cladribine},
  author={Jan O. Liliemark},
  journal={Clinical Pharmacokinetics},
  year={1997},
  volume={32},
  pages={120-131}
}
  • J. Liliemark
  • Published 1997
  • Chemistry, Medicine
  • Clinical Pharmacokinetics
SummaryCladribine is a new purine nucleoside analogue with promising activity in low-grade lymphoproliferative disorders, childhood acute myelogenous leukaemia and multiple sclerosis. Reversed phase high performance liquid chromatography and radioimmunoassay have been used for the analysis of the plasma pharmacokinetics of cladribine. The major (inactive) metabolite in plasma, chloroadenine, can only be detected by liquid chromatography.The oral bioavailability of cladribine is 37 to 51%, and… Expand
Cladribine: a review of its use in multiple sclerosis.
  • H. Langtry, H. Lamb
  • Medicine
  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • 1998
TLDR
Cladribine therapy appears to have the potential to slow the progression of MS, reduce CNS lesions in patients with either the chronic progressive or relapsing-remitting forms of the disease and improve neurological functioning in some of these patients. Expand
Cladribine to Treat Relapsing Forms of Multiple Sclerosis
TLDR
Data from the oral cladribine extension trial and safety register, and reanalysis of the pivotal phase III trial has indicated that oralcladribine is unlikely to be associated with an increased short- to intermediate-term risk of malignancy. Expand
The development impact of cladribine on lymphoid and myeloid cells in multiple sclerosis.
TLDR
This review aims to delineate the development and pharmacological properties of cladribine, and elucidate its influence on lymphoid and myeloid cells in MS. Expand
Cladribine for multiple sclerosis: review and current status
  • J. Sipe
  • Medicine
  • Expert review of neurotherapeutics
  • 2005
TLDR
The proposed study will be the first large multicenter randomized controlled clinical trial of oral cladribine in multiple sclerosis, with evidence of efficacy, tolerability and acceptable side effects/toxicity. Expand
The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
TLDR
Cladribine Tablets are associated with targeted lymphocyte reduction and durable efficacy, with the exposure–effect relationship showing the recommended dose is appropriate in reducing relapse risk. Expand
Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
TLDR
Both CdA and CAde displayed linear PK after intravenous and oral administration of C dA, with Cd a renal function depending on CLCR, and a one-compartment model best described the PK of C Ade. Expand
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
TLDR
A review of all safety data, including lymphopenia, infections, and malignancies, is provided based on data from all trials in patients with MS, including the initial parenteral formulation studies. Expand
Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine
TLDR
In vitro studies examining the inhibitor characteristics of cladribine for a total of 13 major ATP-binding cassette, solute carrier, and CNT transporters indicate that in vivo inhibition of any of thesetransporters bycladribine is unlikely. Expand
Phase I trial of nelarabine in indolent leukemias.
  • V. Gandhi, C. Tam, +5 authors M. Keating
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
Nelarabine is an effective regimen against indolent leukemias, and combining it with fludarabines was most promising, and determination of tumor cell ara-GTP levels may provide a predictive test for response to nelarABine. Expand
Radioiodination and biological evaluation of Cladribine as potential agent for tumor imaging and therapy
Abstract Cladribine, a purine analogue antimetabolite, was radioiodinated with 125I via direct electrophilic substitution reaction. The maximum radiochemical yield (92.5 ± 0.8%) was obtained when theExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
TLDR
Data suggest that cladribine may be useful in the treatment of patients with meningeal leukemia or malignancies of the central nervous system and the first comprehensive description of the pharmacokinetics of this drug in children is provided. Expand
Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.
TLDR
Should early response rates in patients with hairy cell leukaemia be sustained, the efficacy of the drug, together with a short treatment regimen, a favourable tolerability profile, and the possibility of oral therapy, suggest that cladribine is likely to supersede other agents available for this indication. Expand
Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine.
TLDR
In all patients with leukemia, the CdA lowered the blast count by at least 50%, and in one patient with a T-cell leukemia-lymphoma, and in another patient with chronic myelogenous leukemia in blast crisis, theCdA infusion eliminated all detectable blasts from the blood and bone marrow. Expand
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
TLDR
The insertion of two analogs in sequence, inhibition of ribonucleotide reductase, and the metabolic potentiation of ara-CTP by CdA infusion may be responsible for sustained inhibition of DNA synthesis in the circulating leukemia blasts during therapy with this combination regimen. Expand
2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside.
TLDR
2-CdA resists the action of adenosine deaminase and accumulates in cells with high deoxycytidine kinase and low 5'-nucleotidase activity, and is equally toxic to dividing and nondividing cells and may act by preventing repair of DNA single-strand breaks. Expand
On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans.
TLDR
The long terminal half-life of CdA after 2-h infusion supports the use of intermittent infusions, and the interindividual variability of the determinants of the plasma pharmacokinetics of CcdA was small. Expand
Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia.
TLDR
Orally administered cladribine is an effective and feasible therapy for CLL, and produces durable remissions in three quarters of the patients, however, significant toxicity may occur and further studies are required to assess long-term effects and quality-of-life aspects. Expand
A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia.
TLDR
The results of this study confirm the antileukemic activity of 2-CDA and the lack of prohibitive nonhematologic toxicity, and phase II trials in patients with AML and ALL are warranted. Expand
Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia.
TLDR
Subcutaneous injection of CdA is safe and as effective as continuous infusion without problems associated with the mode of administration and can be generally recommended. Expand
2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.
TLDR
2-CDA given by prolonged continuous infusion has clinically significant activity against AML and merits further testing in multidrug regimens for this disease. Expand
...
1
2
3
4
5
...